Skip to main content

Table 3 Postoperative short-term outcomes of each group (N = 353)

From: The effects of preoperative intestinal dysbacteriosis on postoperative recovery in colorectal cancer surgery: a prospective cohort study

Postoperative short-term outcomes Preoperative intestinal dysbacteriosis Sum x2/H P
Grade 1
(n = 268)
Grade 2
(n = 58)
Grade 3
(n = 27)
Early postoperative diarrhoea 38 (14.2%) 25 (43.1%) 13 (48.1%) 76 (21.5%) 32.704  < 0.001
Surgical complications 13 (4.9%) 6 (10.3%) 5 (18.5%) 24 (6.8%) 8.481 0.004
 Incision infections 5 (1.9%) 1 (1.7%) 2 (7.4%) 8 (2.3%) 2.091 0.148
 Abdominal/Pelvic infections 5 (1.9%) 2 (3.4%) 3 (11.1%) 10 (2.8%) 6.470 0.011
 Anastomotic leakage 4 (1.5%) 3 (5.2%) 3 (11.1%) 10 (2.8%) 9.429 0.002
Pulmonary infections 16 (6.0%) 7 (12.1%) 6 (22.2%) 29 (8.2%) 9.733 0.002
Urinary tract infections 3 (1.1%) 1 (1.7%) 0 (0.0%) 4 (1.1%) 0.049 0.824
Fever of unknown origin 2 (0.7%) 1 (1.7%) 0 (0.0%) 3 (0.8%) 0.002 0.963
Total postoperative complications 34 (12.7%) 15 (25.9%) 11 (40.7%) 60 (17.0%) 17.481  < 0.001
Length of postoperative stay (days) 6.0 (3–32) 6.0 (3–32) 6.0 (3–31) 6.0 (3–16) 1.867 0.393
Length of antibiotics therapy (days) 2.0 (1–24) 2.0 (1–24) 3.0 (2–20) 2.0 (1–18) 9.791 0.007
Antibiotics regimen§, n(%)
 Cefoxitin or Cefmetazole 260 (97.0%) 54 (93.1%) 22 (81.5%) 336 (95.2%) 21.163 0.002
 Cefoperazone/sulbactam (Sulperazon) 3 (1.1%) 1 (1.7%) 3 (11.1%) 7 (2.0%)   
 Piperacillin/tazobactam (Tazocin) 2 (0.7%) 2 (3.4%) 2 (7.4%) 6 (1.7%)   
 Moxifloxacin (Avelox) 3 (1.1%) 1 (1.7%) 0 (0.0%) 4 (1.1%)   
  1. The data are presented as n(%) for categorical variables or the median (range) for continuous variables
  2. The P value was obtained by Chi-square test for trend
  3. Pairwise multiple comparisons after Kruskal–Wallis test: grade 1 vs. grade 3, adjusted P < 0.05
  4. §Antibiotic regimen: cefoxitin or cefmetazole, 2.0 g Q8h, Sulperazon 3.0 g Q8h, tazoxin 4.5 g Q8h, avelox 0.4 g Qd